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INTRODUCTION
Radiotherapy has played an important role in treat-
ing carcinoma of the uterine cervix and has contrib-
uted to an improvement in the cure rate (1-3). Ra-
diotherapy, however, also has its limitations in the
treatment of progressive cancer, as does surgery.
Accordingly, extensive studies on radiation sensi-
tizers and adjuvant therapy have been performed,
including radiation therapy combined with chemo-
therapy or immunotherapy.
Kampo (Chinese herbel medicine) therapy was
first introduced in the treatment of cancer patients
from 1978. At the beginning, Kampo applications for
cancer therapy were developed by trial and error
because of dissatisfaction with Western medicine
in dealing with problems such as the side effects of
radiation therapy and chemotherapy and various
types of general malaise. However, routine treat-
ment produced results which were better than ex-
pected (4, 5). This led to rising expectations for the
“ mysteries” of Kampo. As increasing numbers of
reports are now becoming available on cancer ra-
diation therapy, ranging from basic research to clini-
cal studies (6 -9), our colleagues and we decided to
do a retrospective study of the life-prolonging ef-
fects of concomitant treatment with Kampo medi-
cine in combination with Western medicine. The
current report shows the results of not a random-
ized trial that was carried out to evaluate whether
Kampo could prolong survival in patients with uter-
ine cervical cancer.
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MATERIALS AND METHODS
From 1978 to 1998, 174 patients with cervical can-
cer were treated at the Tokushima University Hos-
pital. All patients with squamous cell carcinoma of
the cervix were treated with radiotherapy in com-
bination with Kampo and analyzed for this study. Pa-
tients with the Federation Internationale de Gyne-
cologie et d’Obstetrique (FIGO) Stage, there were
11 patients with Stage IB disease, 11 patients with
Stage IIA, 51 patients with Stage IIB, 9 patients with
Stage IIIA, 60 patients with Stage IIIB, 17 patients
with Stage IVA, and 15 patients with Stage IVB. Pa-
tient age ranged from 34 to 92 years of age (mean,
67 years of age).
For historical controls, we selected 231 patients
treated during the same period in our department
who did not receive Kampo. There were 12 patients
with Stage IB disease, 26 patients with Stage IIA, 64
patients with Stage IIB, 9 patients with Stage IIIA,
61 patients with Stage IIIB, 40 patients with Stage
IVA, and 19 patients with Stage IVB. Patient age
ranged from 35 to 87 years of age (mean, 67 years
of age) (Table 1).
Radiotherapy
The radiotherapy for these patients was essentially
based on the combination of intracavitary brachyther-
apy (ICBT) and external pelvis irradiation.
ICBT was started 1-3 weeks after external pelvis
irradiation. T.A.O. manual afterloading applicators
(10) with low-dose cesium 137 sources were used
routinely for the ICBT. ICBT was performed on a
fractionation schedule with one insertion per week,
giving 3 to 4 fractions during a period of external
pelvis irradiation. The patients received 45-50 Gy at
point A through ICBT, with the external pelvis ir-
radiation being designed to bring the dose to a to-
tal of 40-50 Gy through use of a center shield. The
ICBT dose contribution to the pelvic lymphnodes
was also calculated and additional external pelvis ir-
radiation to the node was given to bring the total
dose to 60 -70 Gy.
External pelvis irradiation was delivered with 6 -
MV X ray 1616 to 1618 cm antero -posterior and
postero -anterior ports in a daily fraction of 1.8-2.0
Gy, 5 fractions/week for 4 to 5.5 weeks. External
irradiation consisted of whole-pelvis irradiation and
pelvis irradiation with central shielding. A center
shield of 3 cm width was arranged to avoid from the
beginning in stage I-II patients and at 30 Gy in stage
III patients. For external irradiation, the weight of
whole-pelvis irradiation was increased and that of
ICBT decreased as the stage became advanced and
tumor volume increased. Since 1981 when computed
tomography (X-CT) scans were introduced at our
hospital, para-aortic lymph node metastasis has been
diagnosed and treated with external irradiation, with
doses 50 Gy delivered over 5 to 6 weeks.
The radiotherapy treatment method used at the
Tokushima University Hospital has remained es-
sentially unchanged for the past 30 years except for
a decrease in the ICBT dose from 58.5 Gy to 43.8
Gy on average after 1969 in order to reduce compli-
cations (11, 12).
Adjuvant therapy
From 1979 to 1991, 34 patients with locally ad-
vanced cancer (stages IIB, III and IV) underwent
systemic chemotherapy concurrently with radio-
therapy. This system B-M therapy consisted of bleo-
mycin and mitomycin-C (bleomycin 5 mg intramus-
cularly daily for 7 days and the next eighth day
mitomycin-C 10 mg intravenously) was employed
1 to 4 cycles (13, 14).
From 1987 to 1997, 21 patients with locally ad-
vanced cancer received intra-arterial chemotherapy
(I-A chemotherapy) concurrently with radiother-
apy. The I-A chemotherapy consisted of a combi-
nation of 50 mg/body cisplatin and 8 mg/body
Table 1. Patients characteristics and treatment methods
Kampo therapy
(+)
Kampo therapy
(--)
Number of patients 174 231
Age range(median,years old) 34-92(67.2) 35-87(66.7)
30 1 5
40 11 13
50 28 37
60 48 64
70 67 88
80 18 24
90 1 -
Clinical stage (FIGO)
Ib 11 12
IIa 11 26
IIb 51 64
IIIa 9 9
IIIb 60 61
IVa 17 40
IVb 15 19
Concurrent chemotherapy 40 32
Maintenance chemotherapy 60 71
Maintenance immunotherapy 125 100
Y. Takegawa, et al. Can Kampo prolong the life of cancer patients100
mitomycin-C administered simultaneously into the
bilateral internal iliac arteries using the balloon oc-
cluded arterial infusion (BOAI) method. The infu-
sion was performed twice during radiotherapy in 3 -
week intervals (15).
In regards to chemotherapy, maintenance therapy
was started in 1978, at which time we reduced the
dose delivered by ICBT. A total of 161 patients under-
went oral administration of 300 mg/day fluorouracil
or 300 mg/day tegafur uracil as a maintenance che-
motherapy, which was performed continuously for
two years following radiotherapy provided no side
effects were observed.
Since 1978, we have been using immunotherapy,
Krestin (PSK) (16), LC-9018 (17) and Z-100 (18)
as Biological Response Modifiers (BRM) combina-
tion therapy for radiotherapy. From 1978 to 1990,
178 patients were treated by oral administration of
3 - 6 g/day PSK and performed continuously for one
year as a rule.
Kampo therapy
Kampo applications for cancer treatment were de-
veloped by trial and error because of dissatisfac-
tion with Western medicine in dealing with prob-
lems such as the side effects of radiation therapy
and various types of general malaise.
The Kampo formulation used were Tsumura
Kampo granulated extracts, given at a dose of 7.5
to 9.0 g/day, 30 minutes before meals, in a small
quantity of hot water. Almost all patients began this
regimen during radiation therapy and continued to
follow it for several years, up to over 20 years in
some cases. Typical Kampo formulations were con-
stitution builders such as Juzentaihoto, Ninjinyoeito
and Hochuekkito with usage designated as tradi-
tional diagnosis “SHO” for both Wazai and Shazai
type formulations (19) (Table 2).
Follow-up
All patients had follow-up for more than 5 years
(minimum 2 to 312 months). Most patient status
was followed once a month for 3 years, then once
every 2 to 3 months for 3 years, 2 to 3 times a year
for 5 years, and once or twice a year for more than
5 years after radiation therapy. The examination
consisted of cystoscopy of the bladder, proctoscopy
or barium enema of the colon and rectum, and rou-
tine blood, urine, and radiographic examinations.
Patient status information was obtained from our
records, by letter, or by telephone contact with pa-
tients or their relatives.
Analyses
Survival times were calculation by setting the
starting point at the initiation of radiation therapy
while survival probability was calculated using the
Kaplan-Meyer method (20). The statistical signifi-
cances of difference in survival rates were calculated
using the Breslow-Gehan-Wilcoxon tests (21, 22).
In the present study, we compared the outcomes
of the Kampotherapty(+) group with those of the
Kampotherapy(--) group. As this study was not a
randomized trial, any possible deviations were cor-
rected with multivariate analysis using Cox’ pro-
portional hazard model (23), and the degree of con-
tribution of each factor to the prognosis was calcu-
lated. The following patient characteristics were con-
sidered for inclusion in the model : age, clinical
stage, concurrent chemotherapy (systemic chemo-
therapy + I-A chemotherapy), maintenance chemo-
therapy and maintenance immunotherapy. Factors
exhibiting a difference at the 0.05 level were con-
sidered statistically significant.
RESULTS
Initial analysis
Fig. 1. show cumulative survivals of patients treated
with Kampo V.S. without Kampo (p0.0001).
Survival rates for 5, 10 and 15 years after treat-
ment with Kampo, respectively, were 90.9%, 71.6%
and 71.6% for Stage IB, 78.9%, 61.8% and 41.8% for
Stage II, 62,3%, 49.1% and 41.2% for Stage III and
53.1%, 36.5% and 16.7% for Stage IV.
For comparison, survival rates for 5, 10 and 15
years after treatment without Kampo, respectively,
were 83.3%, 75.0 % and 64.3% for Stage IB, 66.7%,
42.8% and 23.3% for Stage II, 41.0%, 28.2% and
Table 2. Typical Kampo formuration
Kampo formurations No. of patients
Juzentaihoto 74 (42.5%)
Hatimijiogan 30 (17.2%)
Ninjinyoeito 22 (12.6%)
Saireito 20 (11.5%)
Hochuekkito 11 ( 6.3%)
Shosaikoto 9 ( 5.3%)
Daisaikoto 3 ( 1.7%)
others 20 (11.5%)
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12.9% for Stage III and 20.3%, 11.9% and 2.0% for
Stage IV. Analysis of cumulative survivals of patients
with and without Kampo therapy is shown in Figs.
2, 3 and 4.
Patients Characteristics
Table 1 shows characteristics of the 405 patients
according to the two treatment group comparisons.
Of the 174 to receive Kampo therapy, 40 were to re-
ceive concurrent chemotherapy, 60 were to receive
maintenance chemotherapy and 125 were to receive
maintenance immunotherapy, as 32 of the 231 to
receive no Kampo therapy were to receive concur-
rent chemotherapy, 71 were to receive maintenance
chemotherapy and 100 were to receive maintenance
immunotherapy.
Patients out-comes
Patients out-comes are shown in Table 3. For pa-
tients received Kampo, number of patients alive
without the evidence of local recurrence and distant
metastasis, death of local recurrence and distant
metastasis, death of other cause and unknown were
56(32.2%), 58(33.3%), 39(22.4%) and 21(12.1%), re-
spectively.
For comparison, patients received no Kampo,
number of patients alive without evidence of lo-
cal recurrence and distant metastasis, death of lo-
cal recurrence and distant metastasis, death of
other cause and unknown were 25(10.8%), 120
(51.9%), 67(29.0%) and 19(8.2%), respectively.
Univariate analyses
Table 4 shows the univariate analyses of survival
using the Breslow-Gehan-Wilcoxon tests in 174 pa-
tients who received Kampo and in 231 patients who
received no Kampo. The analyses was performed
in relation to five factors, including age, clinical
stage, concurrent chemotherapy, maintenance che-
motherapy and maintenance immunotherapy. In all
parameters, Kampo did improve the patient prog-
nosis. The adjuvant therapy did not improve the
clinical prognosis in both treatment groups.
Table 3. Patients out-comes
Number of patients Kampo therapy(+)174
Kampo therapy(--)
231
Range of follow up period
(median month) 6-264 (104) 2-312 (75)
Out-comes
Alive 56 (32.2%) 25 (10.8%)
Cancer death 58 (33.3%) 120 (51.9%)
Other death 39 (22.4%) 67 (29.0%)
Unknown 21 (12.1%) 19 ( 8.2%)
Fig. 1. Overall survival in cervical cancer
Fig. 2. Overall survival in cervical cancer (Stage II)
Fig. 3. Overall survival in cervical cancer (Stage III)
Fig. 4. Overall survival in cervical cancer (Stage IV)
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DISCUSSION
In recent years, dramatic advances in molecular
biology have made it possible to analyze complex
physioprotective systems at the molecular level. It
is now important that we utilize this technology both
in accurately assessing Kampo medicine from the
viewpoint of modern science and also in develop-
ing new clinical applications for these products.
Kampo medicine has its roots in Chinese phi-
losophy, as that it differs profoundly from Western
medicine. Theories incorporating the principles of
Yin and Yang and the five elements present a type
of universalism in which everything is considered
in relationship to everything else. The world rep-
resents one universe. Each human body is also a
universe, containing within it the smaller universe
of the organs including the liver, heart, spleen, lung
and kidney. Everything has both a Yin and Tang
aspect, and these aspects repeatedly oppose and
are integrated with each other, so that the uni-
verse operates through cycles of growth and decay,
according to the national philosophy presented by
the Book of Divination (24).
Western medicine has its basis in science. Its ori-
entation is mechanical, statistical and dualistic, with
emphasis on local pathophysiology and the thera-
peutic focus is on the elimination of pathologic fac-
tors. Kampo medicine has its basis in universalism,
and is humanistic, individualized, and monistic in
its approach. The therapeutic focus is primarily on
the functioning of the body, to increase the body’s
natural healing powers against outside factors. This
treatment system also has as its objective the mul-
tifaceted regulation and optimization of physiologic
functions.
A combination of Chinese and Western medicine
began to be practiced in Japan from the 1950s. This
new form of medicine, which combined the rich
legacy of thousands of years of Kampo medical prac-
tice with the penetrating of modern medicine, be-
gan to develop rapidly beginning in the 1980s. Pre-
vious to that, we had already theorized that a new
form of cancer treatment could be developed based
on this combination of Chinese and Western medi-
cine theory. Such treatment would utilize the pow-
erful tools of Western medicine, such as surgery,
radiation, and anticancer drugs, to directly combat
cancer, but these treatments would be combined
with restorative techniques specific to Kampo medi-
cine which would replenish lost vitality and build
up the natural healing powers of the body. There
would also be concomitant use of BRM and other
similar tools from Western medicine. By utilizing
the strengths of both Western and Kampo medi-
cine, this treatment method should provide optimal
cancer therapy.
Our many years of experience with Kampo indi-
cate that it is inappropriate to evaluate these prod-
ucts on the same scale as used to measure the clini-
cal effectiveness of Western medicine. However,
progress has been made in recent years on immu-
Table 4. Univariate analyses of 5-year overall survival
Treatment with Kampo ( 174 patients) without Kampo ( 231 patients)
Factors No. ofpts.
5 -year
survival rate
Breslow-Gehan-
Wilcoxon p-value
No. of
pts.
5 -year
survival rate
Breslow-Gehan-
Wilcoxon p-value
Age 0.5935 0.045
65 years old 64 65.6% 83 39.8%
65 years old= 110 70.8% 148 51.4%
Clinical stage 0.0217 <0.0001
I,II 73 80.7% 102 67.6%
III,IV 101 60.4% 129 31.0%
Concurrent chemotherapy 0.025 0.0041
with 40 52.5% 32 28.1%
without 74 72.8% 128 52,3%
Maintenance chemotherapy 0.6584 0.3603
with 60 75.0% 71 45.1%
without 74 72.8% 128 52,3%
Maintenance immunotherapy 0.4393 0.2970
with 125 69.5% 110 51.8%
without 49 67.3% 121 43.0%
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nologic analysis of cancer patients (9), and the pre-
sent report provides information on survival rates.
Gradually, we are approaching the point where ob-
jective evaluation will be possible.
Initially we began the concomitant administration
of Kampo with the objective of reducing side effects
and improving the quality of life (QOL) of patients
undergoing radiotherapy and chemotherapy. How-
ever, our analysis of these patients showed that
Kampo also provided life-prolonging effects.
In our study, stratified by treatment method, re-
sults from the cases in stage II showed the 5, 10,
and 15 years survival rate were 78.9%, 61.8% and
41.8% treated with Kampo and 66.7%, 42.8% and
23.3% treated without Kampo, respectively (Fig. 2).
Results from the cases in stage III showed the 5,
10, and 15 year survival rate were 62.3%, 49.1% and
41.2% and 41,0%, 28.2% and 12.9%, respectively
(Fig. 3). Results from the cases in stage IV showed
the 5, 10, and 15 years survival rate were 53.1%,
36.5% and 16.7% and 20.3%, 11.9% and 2.0%, respec-
tively (Fig. 4). There was statistically significant dif-
ference in each stage (stage II : p=0.0063, stage III :
p=0.0004, stage IV : p0.0001).
In Japan, various forms of chemotherapy have
been tested in conjunction with radiotherapy with
the objective of prolonging survival in patients with
advanced cervical cancer. However, although these
methods increase the local success rate of cancer
treatment, they do little to prolong survival, and
their use is reportedly accompanied by a higher inci-
dence of side effect (14, 25).
Multivariate analysis on 405 patients in this study
showed that concomitant chemotherapy was not a
significant prognostic indicator of prolonged sur-
vival (p=0.4934). Stage and concomitant Kampo
therapy, however, did emerge as a significant prog-
nostic indicator (p0.0001 and p=0.0001).
We feel sure that further clinical research will
result in the development of new applications for
Kampo preparation, and that a combination of Chi-
nese and Western medicine will prove beneficial in
the treatment of cancer in the 21st Century.
CONCLUSION
Modern cancer treatment, which involves sur-
gery, radiation and chemotherapy, inflicts great
suffering and requires stoic endurance on the part
of the patients. Kampo was introduced into cancer
therapy to improve patient QOL, but has also been
found therapeutically useful in itself. The results of
our study indicate that concomitant Kampo has a
significant positive effect on survival time.
We expect that cancer treatment in the 21st Cen-
tury will maximize the patient’s own natural heal-
ing abilities, and that concepts will be changed and
further efforts will be made to decrease the diffi-
culties of cancer therapy for the patient.
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